
CLAIMS

1. Use of compounds of the general formula (A):




(A)


wherein


R_1 is -C(O)-R_2-C(O)- or -R_2-C(O)- group, where R_2 is -$(CH_2)_n$- group optionally substituted with one or two C_1-C_6 alkyls, or phenyl,


n is an integer from 0 to 4;


wherein compounds are selected from the group consisting of compounds of formula


I 


II 


III 


IV 


V 

VI 

VII 

VIII 

IX 

X 

or pharmaceutically acceptable salts, hydrates, or solvates thereof in the manufacture of a medicament for treatment of a disorder selected from bronchial asthma, acute or chronic bronchitis, pharyngitis, lung emphysema, pain syndrome, rhinitis, rhinosinusitis, chronic obstructive pulmonary disease, acute lung injury, fever, atopic dermatitis, psoriasis, Crohn's disease, ulcerative colitis, obesity, metabolic syndrome, non-alcohol fatty liver disease, nephropathy and peritonitis.

2. The use according to claim 1, wherein the nephropathy represents diabetic nephropathy.

3. The use according to claim 1 or 2, wherein the medicament further comprises at least one other active agent.

4. The use according to claim 3, wherein the at least one other active agent is selected from the group comprising antibacterial, cytostatic and cytotoxic agents, agents inhibiting symptoms or side effects of active agents, and a combination thereof.